Literature DB >> 34180392

Transcription-associated topoisomerase 2α (TOP2A) activity is a major effector of cytotoxicity induced by G-quadruplex ligands.

Madeleine Bossaert1,2, Angélique Pipier1,2, Patrick Calsou1,2, Sébastien Britton1,2, Dennis Gomez1,2, Jean-Francois Riou3, Céline Noirot4, Linh-Trang Nguyên1, Remy-Felix Serre5, Olivier Bouchez5, Eric Defrancq6.   

Abstract

G-quadruplexes (G4) are non-canonical DNA structures found in the genome of most species including human. Small molecules stabilizing these structures, called G4 ligands, have been identified and, for some of them, shown to induce cytotoxic DNA double-strand breaks. Through the use of an unbiased genetic approach, we identify here topoisomerase 2α (TOP2A) as a major effector of cytotoxicity induced by two clastogenic G4 ligands, pyridostatin and CX-5461, the latter molecule currently undergoing phase I/II clinical trials in oncology. We show that both TOP2 activity and transcription account for DNA break production following G4 ligand treatments. In contrast, clastogenic activity of these G4 ligands is countered by topoisomerase 1 (TOP1), which limits co-transcriptional G4 formation, and by factors promoting transcriptional elongation. Altogether our results support that clastogenic G4 ligands act as DNA structure-driven TOP2 poisons at transcribed regions bearing G4 structures.
© 2021, Bossaert et al.

Entities:  

Keywords:  CX-5461; DNA breaks; G-quadruplex; cancer biology; chromosomes; gene expression; human; topoisomerase 2; transcription

Year:  2021        PMID: 34180392     DOI: 10.7554/eLife.65184

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  13 in total

1.  Topoisomerase II poisons inhibit vertebrate DNA replication through distinct mechanisms.

Authors:  Sabrina X Van Ravenstein; Kavi P Mehta; Tamar Kavlashvili; Jo Ann W Byl; Runxiang Zhao; Neil Osheroff; David Cortez; James M Dewar
Journal:  EMBO J       Date:  2022-05-16       Impact factor: 14.012

2.  SDR enzymes oxidize specific lipidic alkynylcarbinols into cytotoxic protein-reactive species.

Authors:  Pascal Demange; Etienne Joly; Julien Marcoux; Yves Génisson; Remi Chauvin; Patrick R A Zanon; Dymytrii Listunov; Pauline Rullière; Cécile Barthes; Céline Noirot; Jean-Baptiste Izquierdo; Alexandrine Rozié; Karen Pradines; Romain Hee; Maria Vieira de Brito; Marlène Marcellin; Remy-Felix Serre; Olivier Bouchez; Odile Burlet-Schiltz; Maria Conceição Ferreira Oliveira; Stéphanie Ballereau; Vania Bernardes-Génisson; Valérie Maraval; Patrick Calsou; Stephan M Hacker; Sébastien Britton
Journal:  Elife       Date:  2022-05-10       Impact factor: 8.713

3.  Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.

Authors:  John Hilton; Karen Gelmon; Philippe L Bedard; Dongsheng Tu; Hong Xu; Anna V Tinker; Rachel Goodwin; Scott A Laurie; Derek Jonker; Aaron R Hansen; Zachary W Veitch; Daniel J Renouf; Linda Hagerman; Hongbo Lui; Bingshu Chen; Deb Kellar; Irene Li; Sung-Eun Lee; Takako Kono; Brian Y C Cheng; Damian Yap; Daniel Lai; Sean Beatty; John Soong; Kathleen I Pritchard; Isabel Soria-Bretones; Eric Chen; Harriet Feilotter; Moira Rushton; Lesley Seymour; Samuel Aparicio; David W Cescon
Journal:  Nat Commun       Date:  2022-06-24       Impact factor: 17.694

Review 4.  Harnessing the Nucleolar DNA Damage Response in Cancer Therapy.

Authors:  Jiachen Xuan; Kezia Gitareja; Natalie Brajanovski; Elaine Sanij
Journal:  Genes (Basel)       Date:  2021-07-28       Impact factor: 4.096

Review 5.  Targeting Ribosome Biogenesis in Cancer: Lessons Learned and Way Forward.

Authors:  Asimina Zisi; Jiri Bartek; Mikael S Lindström
Journal:  Cancers (Basel)       Date:  2022-04-24       Impact factor: 6.575

6.  Dual targeting of higher-order DNA structures by azacryptands induces DNA junction-mediated DNA damage in cancer cells.

Authors:  Joanna Zell; Katerina Duskova; Leïla Chouh; Madeleine Bossaert; Nicolas Chéron; Anton Granzhan; Sébastien Britton; David Monchaud
Journal:  Nucleic Acids Res       Date:  2021-10-11       Impact factor: 16.971

7.  The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma.

Authors:  Min Pan; William C Wright; Richard H Chapple; Asif Zubair; Manbir Sandhu; Jake E Batchelder; Brandt C Huddle; Jonathan Low; Kaley B Blankenship; Yingzhe Wang; Brittney Gordon; Payton Archer; Samuel W Brady; Sivaraman Natarajan; Matthew J Posgai; John Schuetz; Darcie Miller; Ravi Kalathur; Siquan Chen; Jon Patrick Connelly; M Madan Babu; Michael A Dyer; Shondra M Pruett-Miller; Burgess B Freeman; Taosheng Chen; Lucy A Godley; Scott C Blanchard; Elizabeth Stewart; John Easton; Paul Geeleher
Journal:  Nat Commun       Date:  2021-11-09       Impact factor: 14.919

8.  CX-5461 induces radiosensitization through modification of the DNA damage response and not inhibition of RNA polymerase I.

Authors:  Stacey L Lehman; Kayla R Schwartz; Shrankhla Maheshwari; Kevin Camphausen; Philip J Tofilon
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.996

Review 9.  DNA folds threaten genetic stability and can be leveraged for chemotherapy.

Authors:  Joanna Zell; Francesco Rota Sperti; Sébastien Britton; David Monchaud
Journal:  RSC Chem Biol       Date:  2020-09-30

Review 10.  Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies.

Authors:  Caroline Molinaro; Alain Martoriati; Katia Cailliau
Journal:  Cancers (Basel)       Date:  2021-07-29       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.